UnitedHealth Group (NYSE:UNH – Get Rating) issued an update on its FY 2022 earnings guidance on Thursday morning. The company provided earnings per share guidance of $21.200-$21.700 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $21.600. The company issued revenue guidance of -.UnitedHealth Group also updated its FY22 guidance to $21.20-21.70 EPS.
NYSE:UNH opened at $534.82 on Friday. The company has a current ratio of 0.79, a quick ratio of 0.79 and a debt-to-equity ratio of 0.56. UnitedHealth Group has a 12-month low of $380.00 and a 12-month high of $553.29. The stock has a 50-day moving average price of $497.48 and a 200 day moving average price of $470.48. The stock has a market capitalization of $503.21 billion, a P/E ratio of 29.58, a P/E/G ratio of 1.68 and a beta of 0.88.
UnitedHealth Group (NYSE:UNH – Get Rating) last released its earnings results on Thursday, April 14th. The healthcare conglomerate reported $5.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.38 by $0.11. The firm had revenue of $80.15 billion during the quarter, compared to analysts’ expectations of $78.77 billion. UnitedHealth Group had a return on equity of 25.11% and a net margin of 6.01%. The firm’s revenue was up 14.2% on a year-over-year basis. During the same quarter last year, the business posted $5.31 earnings per share. On average, research analysts predict that UnitedHealth Group will post 21.69 earnings per share for the current fiscal year.
A number of brokerages recently issued reports on UNH. BMO Capital Markets raised their price target on UnitedHealth Group from $500.00 to $510.00 and gave the stock a market perform rating in a research note on Friday, January 21st. Sanford C. Bernstein lifted their target price on UnitedHealth Group from $508.00 to $564.00 in a research report on Tuesday, January 11th. SVB Leerink lifted their target price on UnitedHealth Group from $480.00 to $550.00 and gave the company an outperform rating in a research report on Wednesday, January 26th. Deutsche Bank Aktiengesellschaft lifted their target price on UnitedHealth Group from $477.00 to $482.00 and gave the company a buy rating in a research report on Thursday, January 20th. Finally, Raymond James lifted their target price on UnitedHealth Group from $515.00 to $540.00 and gave the company a strong-buy rating in a research report on Friday, January 21st. Two research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, UnitedHealth Group has an average rating of Buy and an average target price of $510.17.
In other news, Director Richard T. Burke sold 3,000 shares of UnitedHealth Group stock in a transaction that occurred on Thursday, March 24th. The shares were sold at an average price of $508.80, for a total transaction of $1,526,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard T. Burke sold 4,000 shares of UnitedHealth Group stock in a transaction that occurred on Tuesday, March 22nd. The shares were sold at an average price of $511.14, for a total transaction of $2,044,560.00. The disclosure for this sale can be found here. Insiders have sold a total of 23,000 shares of company stock valued at $11,123,890 over the last three months. 0.55% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Crestwood Advisors Group LLC boosted its stake in UnitedHealth Group by 5.1% during the 4th quarter. Crestwood Advisors Group LLC now owns 934 shares of the healthcare conglomerate’s stock worth $469,000 after purchasing an additional 45 shares during the last quarter. Camden National Bank grew its holdings in shares of UnitedHealth Group by 5.5% in the fourth quarter. Camden National Bank now owns 1,902 shares of the healthcare conglomerate’s stock valued at $667,000 after purchasing an additional 100 shares during the period. Neo Ivy Capital Management acquired a new stake in UnitedHealth Group during the fourth quarter worth about $82,000. Flagship Harbor Advisors LLC grew its stake in shares of UnitedHealth Group by 12.7% in the 4th quarter. Flagship Harbor Advisors LLC now owns 5,655 shares of the healthcare conglomerate’s stock valued at $2,840,000 after buying an additional 636 shares during the period. Finally, Autumn Glory Partners LLC acquired a new position in UnitedHealth Group in the fourth quarter valued at approximately $638,000. 86.07% of the stock is currently owned by institutional investors.
About UnitedHealth Group (Get Rating)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage and well-being services to individuals age 50 and older addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance and health care programs; health and dental benefits; and hospital and clinical services.
- Get a free copy of the StockNews.com research report on UnitedHealth Group (UNH)
- Array Technologies Stock Giving Another Ground Floor Entry
- UiPath Stock is Nearing Rock Bottom Down Here
- 3 Undervalued S&P 500 Stocks to Buy Now
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
- Lululemon Rises On Wave Of Price Target Increases
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.